MXPA02002486A - Uso de dexrazoxano para tratar la psoriasis. - Google Patents
Uso de dexrazoxano para tratar la psoriasis.Info
- Publication number
- MXPA02002486A MXPA02002486A MXPA02002486A MXPA02002486A MXPA02002486A MX PA02002486 A MXPA02002486 A MX PA02002486A MX PA02002486 A MXPA02002486 A MX PA02002486A MX PA02002486 A MXPA02002486 A MX PA02002486A MX PA02002486 A MXPA02002486 A MX PA02002486A
- Authority
- MX
- Mexico
- Prior art keywords
- dexrazoxane
- treating psoriasis
- psoriasis
- treating
- dioxopiperazin
- Prior art date
Links
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 title abstract 2
- 201000004681 Psoriasis Diseases 0.000 title abstract 2
- 229960000605 dexrazoxane Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT155899 | 1999-09-10 | ||
US18380600P | 2000-02-22 | 2000-02-22 | |
PCT/EP2000/008879 WO2001019358A2 (fr) | 1999-09-10 | 2000-09-08 | Compositions pharmaceutiques destinees au traitement du psoriasis |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02002486A true MXPA02002486A (es) | 2004-09-10 |
Family
ID=25596169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02002486A MXPA02002486A (es) | 1999-09-10 | 2000-09-08 | Uso de dexrazoxano para tratar la psoriasis. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1214073A2 (fr) |
KR (1) | KR20020035131A (fr) |
CN (1) | CN1378451A (fr) |
AU (1) | AU7286500A (fr) |
BG (1) | BG106428A (fr) |
BR (1) | BR0013921A (fr) |
CA (1) | CA2384685A1 (fr) |
CZ (1) | CZ2002729A3 (fr) |
EE (1) | EE04871B1 (fr) |
HR (1) | HRPK20020201B1 (fr) |
HU (1) | HUP0202791A3 (fr) |
MX (1) | MXPA02002486A (fr) |
PL (1) | PL354980A1 (fr) |
RU (1) | RU2002106874A (fr) |
SK (1) | SK2802002A3 (fr) |
WO (1) | WO2001019358A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021053523A1 (fr) * | 2019-09-18 | 2021-03-25 | Tryp Therapeutics | Compositions et procédés pour améliorer l'effet thérapeutique de bis-dioxopipérazines |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3941790A (en) * | 1967-07-03 | 1976-03-02 | National Research Development Corporation | Bis diketopiperazines |
GB1234935A (en) * | 1967-07-03 | 1971-06-09 | Nat Res Dev | Piperazine derivatives |
US4963679A (en) * | 1988-02-17 | 1990-10-16 | Erbamont, Inc. | Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes |
JPH09503749A (ja) * | 1993-07-23 | 1997-04-15 | エルエックスアール バイオテクノロジー インコーポレイテッド | アポトーシスおよび関連した状態の処置方法 |
-
2000
- 2000-09-08 WO PCT/EP2000/008879 patent/WO2001019358A2/fr not_active Application Discontinuation
- 2000-09-08 CZ CZ2002729A patent/CZ2002729A3/cs unknown
- 2000-09-08 BR BR0013921-1A patent/BR0013921A/pt not_active Application Discontinuation
- 2000-09-08 HU HU0202791A patent/HUP0202791A3/hu unknown
- 2000-09-08 EP EP00960646A patent/EP1214073A2/fr not_active Withdrawn
- 2000-09-08 AU AU72865/00A patent/AU7286500A/en not_active Abandoned
- 2000-09-08 KR KR1020027003049A patent/KR20020035131A/ko not_active Application Discontinuation
- 2000-09-08 CA CA002384685A patent/CA2384685A1/fr not_active Abandoned
- 2000-09-08 MX MXPA02002486A patent/MXPA02002486A/es unknown
- 2000-09-08 CN CN00812682A patent/CN1378451A/zh active Pending
- 2000-09-08 SK SK280-2002A patent/SK2802002A3/sk not_active Application Discontinuation
- 2000-09-08 EE EEP200200128A patent/EE04871B1/xx not_active IP Right Cessation
- 2000-09-08 RU RU2002106874/14A patent/RU2002106874A/ru not_active Application Discontinuation
- 2000-09-08 PL PL00354980A patent/PL354980A1/xx not_active Application Discontinuation
-
2002
- 2002-02-22 BG BG106428A patent/BG106428A/xx unknown
- 2002-03-05 HR HR20020201A patent/HRPK20020201B1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1378451A (zh) | 2002-11-06 |
KR20020035131A (ko) | 2002-05-09 |
EP1214073A2 (fr) | 2002-06-19 |
WO2001019358A3 (fr) | 2001-10-04 |
AU7286500A (en) | 2001-04-17 |
PL354980A1 (en) | 2004-03-22 |
CZ2002729A3 (cs) | 2002-07-17 |
SK2802002A3 (en) | 2003-02-04 |
BG106428A (en) | 2003-04-30 |
BR0013921A (pt) | 2002-05-14 |
HUP0202791A2 (hu) | 2003-01-28 |
RU2002106874A (ru) | 2003-11-20 |
WO2001019358A2 (fr) | 2001-03-22 |
HRP20020201A2 (en) | 2003-06-30 |
HRPK20020201B1 (en) | 2004-08-31 |
EE200200128A (et) | 2003-04-15 |
EE04871B1 (et) | 2007-08-15 |
CA2384685A1 (fr) | 2001-03-22 |
HUP0202791A3 (en) | 2003-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG106586A (en) | Pyrazolopyramidines as therapeutic agents | |
MY118151A (en) | Pharmaceutical formulations containing voriconazole. | |
BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
MY134892A (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use | |
BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
MX9204625A (es) | Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva. | |
TR200000812T2 (tr) | 2-metil-tieno- benzodiazepin formülasyonu. | |
BG105556A (en) | New esters derived from substituted phenyl-cyclohexyl compounds | |
PL369999A1 (en) | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivatives or salts thereof | |
GEP20094818B (en) | 2-methyl-thieno-benzodiaze-pine formulation | |
DE69841267D1 (de) | Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit | |
BG104038A (en) | Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing | |
GB9907571D0 (en) | Compounds | |
HUP0202592A2 (hu) | Lazofoxifen transzdermális adagolása | |
NZ515685A (en) | Use of riluzole for the treatment of multiple sclerosis | |
MY128529A (en) | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
MXPA02002486A (es) | Uso de dexrazoxano para tratar la psoriasis. | |
IL158186A0 (en) | Pharmaceutically active compounds and methods of use | |
RS51316B (sr) | Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli | |
DE69426021D1 (de) | Xamonelin-Tartrat | |
AP2001002369A0 (en) | Pharmaceutical complex. | |
ATE323493T1 (de) | Gesteuerte freisetzung von antidepressiva | |
MXPA03009723A (es) | Procedimientos e intermediarios para preparar epoxidos substituidos de bencilo. | |
CO5021190A1 (es) | Agentes terapeuticos | |
RS47804A (en) | 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof |